Tyvaso Dpi is owned by United Therap.
Tyvaso Dpi contains Treprostinil.
Tyvaso Dpi has a total of 6 drug patents out of which 0 drug patents have expired.
Tyvaso Dpi was authorised for market use on 23 May, 2022.
Tyvaso Dpi is available in powder;inhalation dosage forms.
Tyvaso Dpi can be used as method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device.
The generics of Tyvaso Dpi are possible to be released after 01 April, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US9593066||UNITED THERAP||Process to prepare treprostinil, the active ingredient in remodulin®|| |
(5 years from now)
|US9604901||UNITED THERAP||Process to prepare treprostinil, the active ingredient in Remodulin®|| |
(5 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10130685||UNITED THERAP||Diketopiperazine salts for drug delivery and related methods|| |
(2 years from now)
|US10716793||UNITED THERAP||Treprostinil administration by inhalation|| |
(3 years from now)
|US10772883||UNITED THERAP||Diketopiperazine microparticles with defined specific surface areas|| |
(7 years from now)
|US10421729||UNITED THERAP||Microcrystalline diketopiperazine compositions and methods|| |
(11 years from now)
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic